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Abstract 
In this work we report a synthetic strategy of amphiphilic DOTA-based chelators 
bearing a variable size α-alkyl chain at one of the pendant acetate arms (from six to 
fourteen carbon atoms), compatible with their covalent coupling to amine-bearing 
biomolecules. The amphiphilic behavior of the micelles-forming Ga(III) chelates 
(critical micelle concentration), their stability in blood serum and their lipophilicity 
(logP) were investigated. Biodistribution studies with the 67Ga-labeled chelates were 
performed in Wistar rats showing a predominant liver uptake with almost no traces of 
the radiochelates in the body after 24 hours. 
 
1. Introduction 
Gallium offers three useful radioisotopes for medical imaging, 67Ga (t1/2 = 3.25 days), 
66Ga (t1/2 = 9.5 h) and 68Ga (t1/2 = 68 min). The first one, a γ emitter, can be used for γ-
scintigraphy, while the others, being β+ emitters, are adequate for positron emission 
tomography (PET). 68Ga is a very attractive radionuclide for PET as it can be produced 
in loco from a 68Ge generator allowing easy routine manufacture in the hospital 
facilities, similar to what happens with the 99Mo/99mTc-generator. Gallium-based 
radiopharmaceuticals preparation is easy and fast, contrarily to the preparation of 18F or 
11C covalently labeled PET agents, leading to a minimum loss of activity [1, 2]. The 
most important requirements for a Ga(III)-based radiopharmaceutical agent are the 
thermodynamic stability and the kinetic inertness during the period of clinical use in 
order to avoid ligand exchange with the blood serum proteins, such as transferrin (Tf) 
[3]. 
Ga(III) is a hard acidic cation that forms thermodynamically stable chelates with ligands 
displaying multiple anionic oxygen donor sites. Several ligands have been used to 
sequester Ga(III) up to its maximum octa-coordination forming pseudo-octahedral 
structures [4]. The macrocyclic ligands NOTA (1,4,7-triazacyclononane-1,4,7-triacetic 
acid) and DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) are 
commonly used for Ga(III) [5, 6] as both provide highly stable chelates. Despite the 
relatively lower thermodynamic stability of the DOTA complex (approximately 10 
orders of magnitude) than that of Ga(III)-NOTA [6], DOTA presents the advantages of 
being commercially better available and of having a less arduous synthesis. DOTA is 
also advantageous considering that it can more than saturate gallium´s common six-
coordination sphere [7], offering two free carboxymethyl arms for conjugation to 
targeting molecules [8, 9, 10]. Additionally DOTA is known to form stable complexes 
with many other radiometals such as In(III), Cu(II), Y(III), lanthanide(III) ions or 
Ac(III) [8, 11, 12]. 
In a previous publication we reported the synthesis of a small library of four 
amphiphilic NOTA-based chelators for Ga(III) presenting a α-alkyl chain of variable 
size bound at one of the pendant arms [13]. These ligands showed to form micelles in 
solution. Micelles are known to constitute efficient drug carriers that can improve its 
pharmacokinetic properties or its bioavailability; likewise they can increase the target-
to-background ratio of the drug or to deliver hydrophobic molecules [14-17]. These 
colloidal particles tend to accumulate in macrophage-rich tissues, undergoing 
endocytosis/phagocytosis [14, 18]. 125I, 111In or 153Sm labeled micelles have been used 
for the scintigraphic visualization of macrophage-rich tissues such as lymph nodes, liver 
and spleen [19-21]. 
In this paper we describe the synthesis and characterization of three amphiphilic DOTA-
derivative chelators, bearing in one of the acetate arms a α-alkyl chain with a variable 
number of carbon atoms (from six to fourteen atoms, see scheme 1). The critical micelle 
concentration (cmc) values of their Ga(III) chelates have been determined by a
fluorescent method based on the use of ANS (8-anilino-1-napthalene sulfonic acid) 
[22]. The stability of the 67Ga(III) labeled chelates in blood serum has been  
investigated. Biodistribution studies of the 67Ga(III) labeled chelates have been 
performed in Wistar rats. 
 
2. Experimental 
2.1. Materials and methods 
Analytical grade reagents were purchased from Sigma-Aldrich, Fluka, Acros Organics 
and Chematech. [67Ga](citrate) was purchased from [67Ga](citrate) was purchased from 
CIS-BIO (Gif-sur- Yvette, France). The reactions were monitored by thin layer 
chromatography (TLC) on aluminum plates coated with silica gel 60 F254 (Macherey 
Nagel). Chromatographic separations were performed on silica gel Whatman 230-240 
Mesh. The NMR spectra were recorded on a Varian Unity Plus 300 spectrometer or on 
a Bruker Avance III 400 spectrometer. The 1H chemical shifts are reported in ppm, 
relative to TMS and the following abbreviations are used: s = singlet; sb = broad singlet; 
d = doublet; dd = double doublet; t = triplet; tb = broad triplet; m = multiplet; mb = 
broad multiplet. pH measurements were performed on a pH meter Crison micro TT 
2050 with an electrode Mettler Toledo InLab 422. Mass spectra (ESI+) were performed 
on a VG Autospec M spectrometer or on a Finnigan LXQ MS Detector. 
The ITLC-SC stripes (instant thin layer chromatograpy) used for the control of the 
radiochemical purity of the [67Ga]L solutions were from Gelman Sciences Inc. 
 
 
 
2.2. Synthetic procedures 
2.2.1. Diphenyldiazomethane (DDM) 
DDM was prepared according to the method of Miller [23]. To 10.03 g of 
benzophenonehydrazone (51.1 mmol), 11.51 g of anhydrous sodium sulfate, 26.91 g of 
yellow mercuric oxide (II) (124.2 mmol) and 3.8 mL of ethanol saturated with 
potassium oxide, 160 mL of ethyl ether were added and the suspension was stirred in a 
1 L round flask at room temperature during 75 minutes. The reaction mixture was 
filtered by gravity and the solvent removed from the filtrate under reduced pressure. The 
dark red oil thus obtained was dissolved in petroleum ether 40-60 ºC and filtered again 
by gravity. The solvent was evaporated under reduced pressure giving a dark red oil 
which was left to freeze. When heated to room temperature it afforded 9.90 g of dark 
red crystals (99.7%). 
2.2.2.1 – 2-Bromooctanoic acid benzhydryl ester (4) 
A solution of 2.56 g of DDM (13.19 mmol) in 90 mL of acetone was added over 
a period of 2 hours to a solution of 2.5 mL of 2-bromooctanoic acid (1) (14.51 mmol) in 
110 mL of acetone. This mixture was kept with stirring in an ice bath during 12 hours 
and then left at room temperature for an additional 12 hours until the red color of DDM 
had vanished. The acetone was evaporated under reduced pressure and a yellow oil was 
obtained. This oil was purified by column chromatography over silica gel 60 
(cyclohexane/ethyl acetate 4:1). 5.12 g of a yellow oil (99.8%) were obtained. 1H NMR 
(300 MHz, CDCl3, SiMe4, δ): 0.89 (t, 3H, J=6.6 Hz, CH3), 1.24-1.30 (m, 8H, CH2), 
1.96-2.18 (m, 2H, CHBr-CH2), 4.34 (t, 1H, J=7.2 Hz, CHBr), 6.92 (s, 1H, CHPh2), 7.36 
(m, 10H, Ph2). 
 
 
2.2.3.1 – 2-Bromodecanoic acid benzhydryl ester (5) 
Using a similar procedure with 2-bromodecanoic acid (2), 6.78 g (99.0%) of a 
yellow oil were obtained. 1H NMR (300 MHz, CDCl3, SiMe4, ): 0,95 (t, 3H, J=6.6 Hz, 
CH3), 1.25-1.44 (m, 12H, CH2), 2.00-2.22 (m, 2H, CHBr-CH2), 4.38 (t, 1H, J=8.3 Hz, 
CHBr), 6.97 (s, 1H, CHPh2), 7.31-7.46 (m, 10H, Ph2). 
2.2.4.1 – 2-Bromohexadecanoic acid benzhydryl ester (6) 
Using a similar procedure with 2-bromohexadecanoic acid (3),  6.04 g (94.0%) 
of a yellow oil were obtained. 1H NMR (300 MHz, CDCl3, SiMe4, ): 0.93 (t, 3H, J=6.8 
Hz, CH3), 1.17-1.42 (m, 24H, CH2), 1.98-2.20 (m, 2H, CHBr-CH2), 4.35 (t, 1H, J=7.4 
Hz, CHBr), 6.94 (s, 1H, CHPh2), 7.30-7.43 (m, 10H, Ph2). 
2.2.2.2 – 1,4,7,10-tetraazacyclododecane-1-(2-carboxyheptyl) benzhydryl ester (7) 
199.3 mg of 1,4,7,10-tetraazacyclododecane (1.16 mmol) were dissolved in 10 
mL of dichloromethane and to this solution a second solution of 347.3 mg of 2-
bromooctanoic acid benzhydryl ester (4) (0.89 mmol) in 10 mL of dichloromethane was 
added over a period of 1.5 hours. The mixture was stirred overnight at room 
temperature, filtered under vacuum and concentrated under reduced pressure, affording 
a brown oil. This oil was purified by column chromatography over silica gel 60 
(dichloromethane/ethanol 7:3, later dichloromethane/ethanol/ammonia 7:3:0.5). At the 
end 211.1 mg of a yellow oil (49.9%) were obtained. 1H NMR (300 MHz, CDCl3, 
SiMe4, ): 0.83 (t, 3H, J=6.8 Hz, CH3), 1.12-1.36 (m, 8H, CH2), 1.74-1.89 (m, 2H, 
CHN-CH2), 2.42-3.40 (m, 16H, NCH2), 6.87 (s, 1H, CHPh2), 7.19-7.36 (m, 10H, Ph2). 
2.2.3.2 – 1,4,7,10-tetraazacyclododecane-1-(2-carboxynonyl) benzhydryl ester (8) 
Using a similar procedure with the convenient ester (5), 1.5 g (65.7%) of a 
yellow oil were obtained. 1H NMR (300 MHz, CDCl3, SiMe4, ): 0.88 (t, 3H, J=6.2 Hz, 
CH3), 1.16-1.41 (m, 12H, CH2), 1.81-1.97 (m, 2H, CHN-CH2), 2.22-3.63 (m, 16H, 
NCH2), 4.19-4.35 (m, 1H, CHN), 6.92 (s, 1H, CHPh2), 7.22-7.41 (m, 10H, Ph2). 
2.2.4.2 – 1,4,7,10-tetraazacyclododecane-1-(2-carboxypentadecyl) benzhydryl ester 
(9) 
Using a similar procedure with the convenient ester (6), 279.4 mg (42,5%) of a 
yellow oil were obtained. 1H NMR (300 MHz, CDCl3, SiMe4, ): 0.87 (t, 3H, J=7.2 Hz, 
CH3), 1.15-1.42 (m, 24H, CH2), 1.74-3.61 (m, 18H, CHN-CH2, NCH2), 4.28-4.37 (m, 
1H, CHN), 6.91 (s, 1H, CHPh2), 7.24-7.42 (m, 10H, Ph2). 
2.2.2.3 – 1,4,7,10-tetraazacyclododecane-1-(2-carboxyheptyl) benzhydryl ester-
4,7,10-triacetic acid tert-butyl ester (10) 
211.3 mg of 1,4,7,10-tetraazacyclododecane-1-(2-carboxyheptyl) benzhydryl 
ester (7) (0.44 mmol) were dissolved in 10 mL of acetonitrile and to this solution, 364.8 
mg of potassium carbonate (2.63 mmol) and 208 l of tert-butyl bromoacetate (1.41 
mmol) were added. The mixture was stirred overnight at room temperature, filtered 
under vacuum and concentrated under reduced pressure to afford a brown oil. This oil 
was purified by column chromatography over silica gel 60 (dichloromethane/ethanol 
7:3). At the end it was obtained 253.3 mg of a brown oil (70,1%). 1H NMR (300 MHz, 
CDCl3, SiMe4, ): 0.77 (t, 3H, J=7.3 Hz, CH3), 1.08-1.30 (m, 8H, CH2), 1.39 (s, 27H, 
C(CH3)3), 1.55-1.71 (m, 2H, CHN-CH2), 1.90-3.50 (m, 22H, NCH2,CH2-COOtBu), 
6.78 (s, 1H, CHPh2), 7.15-7.29 (m, 10H, Ph2). 
2.2.3.3 – 1,4,7,10-tetraazacyclododecane-1-(2-carboxynonyl) benzhydryl ester-
4,7,10-triacetic acid tert-butyl ester (11) 
Using a similar procedure with the convenient compound (8), 985.0 mg (70.8 %) 
of a brown oil were obtained. 1H NMR (300 MHz, CDCl3, SiMe4, ): 0.89 (t, 3H, J=7.0 
Hz, CH3), 1.16-1.37 (m, 12H, CH2), 1.49 (s, 27H, C(CH3)3), 1.83-3.81 (m, 24H, NCH2, 
CHN-CH2,CH2-COOtBu), 6.89 (s, 1H, CHPh2), 7.26-7.40 (m, 10H, Ph2). 
2.2.4.3 – 1,4,7,10-tetraazacyclododecane-1-(2-carboxypentadecyl) benzhydryl 
ester-4,7,10-triacetic acid tert-butyl ester (12) 
Using a similar procedure with the convenient compound (9), 142.9 mg (32.4%) 
of a brown oil were obtained. 1H NMR (300 MHz, CDCl3, SiMe4, ): 0.86 (t, 3H, J=6..8 
Hz, CH3), 1.15-1.37 (m, 24H, CH2), 1.43-1.47 (m, 27H, C(CH3)3), 1.63-1.80 (m, 2H, 
CHN-CH2), 1.96-3.59 (m, 22H, NCH2, CH2-COOtBu,), 6.86 (s, 1H, CHPh2), 7.24-7.38 
(m, 10H, Ph2). 
2.2.2.4 – 1,4,7,10-tetraazacyclododecane-1-(2-carboxyheptyl)-4,7,10-triacetic acid 
(DOTAC8  (13)) 
 253.3 mg of 1,4,7,10-tetraazacyclododecane-1-(2-carboxyheptyl) acid 
benzhydryl ester-4,7,10-triacetic acid tert-butyl ester (10) (0.31 mmol) were dissolved 
in 5 mL of trifluoroacetic acid (98%). The mixture was stirred overnight at room 
temperature and concentrated under reduced pressure affording a brown oil which was 
washed with 3x70 mL of water. The aqueous solution was filtered with a cellulose 
membrane and concentrated under reduced pressure, affording 183.0 mg of a crystalline 
brown solid (62.9%). MS (ESI+): m/z (relative intensity): 511.58 (MNa+, 100). 
2.2.3.4 – 1,4,7,10-tetraazacyclododecane-1-(2-carboxynonyl)-4,7,10-triacetic acid 
(DOTAC10 (14)) 
 The same procedure with the convenient compound (11) afforded 455.0 mg 
(67.4%) of a crystalline brown solid. MS (ESI+): m/z (relative intensity): 517.58 (MH+, 
100). 
 
 
 2.2.4.4 – 1,4,7,10-tetraazacyclododecane-1-(2-carboxypentadecyl)-4,7,10-triacetic 
acid (DOTAC16 (15)) 
 The same procedure with the convenient compound (12) afforded 119.2 mg 
(65.3%) of a crystalline brown solid. MS (ESI+): m/z (relative intensity): 601.42 (MH+, 
100). 
2.3. Determination of the critical micellar concentration 
 The cmc value can be estimated by a fluorescence method using the ANS as 
fluorescent probe [22]. The emission intensities of ANS were obtained at 25 °C in 
microplates optimized for fluorescence where the excitation wavelength used was 350 
nm, while the wavelength of recorded emission was 480 nm. Measurements were made 
in 1 M phosphate buffer (pH 7.4), where every microplate well contained a known 
amount of chelate and 1x10-5 M ANS. The fluorescence measurements were recorded 
on a Bio-Tek® SynergyTM HT spectrofluorimeter using the software KC4TM. 
 The chelates were prepared by adding an equivalent quantity of Ga(III) nitrate to 
a weighted quantity of ligand, dissolving in water at pH 4 and heating at 75oC over 1 
hour. The water was evaporated and the solid was redissolved in phosphate buffer pH 
7.4. In order to know the exact number of ligand equivalents existing in a weighted 
amount of ligand, an excess of a standard Al(III) solution was added to a weighted 
quantity of ligand, leaving the complexation to occur at 75oC. To this solution an excess 
of a standard EDTA solution was added and this was back-titrated with a standard 
Ca(II) solution using eriochrome black T as indicator [24]. 
2.4. Radiochemistry 
 [67Ga] chelates for in vivo and in vitro experiments were prepared by adding 1 
mCi of [67Ga](citrate) to a solution of 1 mg of the chelator in HEPES (0.150 mL, 0.1 M, 
pH 5) and heated at 80 ºC for ca 1 h. The radiochemical purity of the [67Ga]L solutions 
was determined either by TLC eluting with methanol or using ITLC-SC stripes eluting 
with a saline/acetic acid (9:1) mixture. In the first case the 67Ga(III) ion remains in the 
origin and [67Ga]L migrates (rf=0.6) while in the second case [67Ga]L remains in the 
origin and the 67Ga(III) ion migrates (rf=0.8). The percentage of bound metal averaged 
96%. 
2.4.1. Determination of logP and stability in blood serum 
 The octanol/water partition coefficients (logP) of [67Ga](DOTAC8)-, 
[67Ga](DOTAC10)- and [67Ga](DOTAC16)- were determined using the shake-flask 
method. The partition coefficient was determined by adding 25 L of the chelate 
solution to a tube containing 1 mL of saline solution and 1 mL of 1-octanol. The 
resulting mixture was shaken at room temperature for 1 h and then centrifuged at 3000 
rpm during 3 min. After the centrifugation, 100 L of each phase were collected and the 
activity was measured. The partition coefficient was calculated as a ratio of the counts 
in the octanol fraction to the counts in the water fraction being this the result of the 
average of 5 determinations (S.D. < 0.01). 
 For the blood serum stability studies, 5 Ci of the standard solution of 
[67Ga](DOTAC10)- were added to 5 mL of fresh human serum, previously equilibrated 
in 5% CO2 (95% air) environment at 37 ºC. The mixture was stored in the same 
environment conditions, and aliquots of 100 mL (in triplicate) were taken at appropriate 
periods of time (0 min, 30 min, 1 h and 3 h). The aliquots were treated with 200 L of 
ethanol, cooled (4 ºC), and centrifuged during 15 min at 4000 rpm, at 4 ºC, in order to 
precipitate the serum proteins. A 100 L aliquot of supernatant was collected for 
activity counting in a  well-counter. The sediment was washed twice with 1 mL of 
ethanol and its activity was counted. The activity of the supernatant was compared to 
that of the sediment in order to determine the percentage of the chelate associated to the 
proteins. The activity of the supernatant at 3 h was evaluated by TLC in order to check 
whether the chelate remained intact. 
2.4.2. Biodistribution studies 
 Groups of four animals (Wistar rat males weighting ca 200 g) were 
anaesthetized with Ketamine (50.0 mg/mL)/chloropromazine (2.5%) (10:3) and injected 
in the tail vein with ca 100 Ci of the tracer and sacrificed 30 min and 24 h later. The 
major organs were removed, weighted and counted in a  well-counter.  
 
3. Results and discussion 
3.1. Synthesis  
In the preparation of the ligands described in this work, an orthogonal protection 
strategy was followed using protecting groups for the carboxylic moieties that may be 
cleaved, if wished, at two different moments. Such groups were the tert-butyl ester 
(cleaved in acid) and the benzhydryl ester (cleaved through Pd catalyzed hydrogenolysis 
or in acid). This synthetic strategy is compatible with the preparation of bifunctional 
ligands that, after cleavage of the single benzhydryl ester, can be covalently coupled to 
targeting biomolecules with a free amine group. Preliminary coupling experiments with 
linear RGD peptides have shown this strategy to be very effective [results not 
published]. The targeting of the prochelators with suitable biomolecules is of chief 
importance for receptor mediated medical imaging or radiotherapeutic applications [8, 
9]. In this work we treated the pro-chelators 10-12 at once with TFA, affording the 
unprotected chelators DOTAC8, DOTAC10 and DOTAC16 (13-15).  
 
 
3.2 Determination of the critical micellar concentration 
 Micelles formation by amphiphilic compounds occurs above the critical micellar 
concentration (cmc), and this value can be determined by a fluorescence method using 
ANS as fluorescent probe. This aromatic molecule has fluorescent properties that 
depend on the polarity of the medium. Therefore, in polar media like water ANS is not 
fluorescent, whereas in nonpolar media such as the interior of the micelles it is fairly 
luminescent [22]. The cmc values of [Ga(DOTAC8)-], [Ga(DOTAC10)-] and 
[Ga(DOTAC16)-] chelates were estimated by linear least-square fitting of the 
fluorescence emission at 480 nm versus the concentration of the chelates (Fig. 1). The 
calculated cmc values were 3.98 mM for [Ga(DOTAC8)]-, 3.13 mM for 
[Ga(DOTAC10)]- and 0.87 mM for [Ga(DOTAC16)]-, showing, as expected, a decrease 
of the cmc value with the increase of the alkyl chain, reflecting a superior capacity to 
self-aggregate by the longer alkyl chain chelates. Although a correlation between the 
alkyl chain length and the cmc value can be observed, the aqueous behavior of the three 
systems is quite different. For the [Ga(DOTAC8)]- and [Ga(DOTAC16)]- systems, there 
is a substantial increase in the fluorescence intensity with the increase of the chelate 
concentration until the cmc value is reached, and a smaller increase in the fluorescence 
intensity after de cmc. Such behavior is not shown by the [Ga(DOTAC10)]- system, 
suggesting that [Ga(DOTAC8)]- and [Ga(DOTAC16)]-  might form pre-micellar 
aggregates. The formation of pre-micellar aggregates has been previously reported by 
Torres et al for the chelate [Gd(EPTPAC16)]2-, which formed particles with dimensions 
superior to 100 nm below the cmc, as detected by DLS [25]. The cmc value obtained for 
[Ga(DOTAC16)]- is comparable to the value found for the amphiphilic Gd(III) chelate 
with the same alkyl chain length [26].  
 
3.3 Determination of logP 
 The calculated values of the octanol/water partition coefficients (logP) were -
2.83 for [67Ga](DOTAC8)-, -1.50 for [67Ga](DOTAC10)- and 0.27 for 
[67Ga](DOTAC16)-. These values show that the chelates are highly hydrophilic, and, as 
expected, the hydrophylicity decreases with the increasing size of the -alkyl chain. 
3.4 Stability in blood serum  
 Incubation studies of [67Ga](DOTAC10)- in fresh human serum, followed by 
precipitation of its protein content, showed that the percentage of the activity in the 
protein pellet steadily increased with the incubation time (6.25% at 0 min, 9.07% at 60 
min), reaching a value of 12.57% at 3 h. The increasing activity associated to the blood 
proteins can be explained by the hydrophobic interactions involving the -alkyl 
substituent and the hydrophobic regions of the proteins, and it is expected that this 
interaction can increase with the increasing size of the -alkyl side chain. 
 The stability of the chelate was verified through TLC analysis, where the 
radioactivity present in the fraction 3 h after incubation was measured and analyzed. It 
was found that after this time the radiochelate was intact, reflecting the high stability of 
[67Ga](DOTAC10)- towards transchelation. 
3.5 Biodistribution studies 
 The biodistribution data for [67Ga](DOTAC10)- and [67Ga](DOTAC16)- are 
expressed as the percentage of injected dose per gram of tissue (%ID/g) in Fig. 2. At 30 
minutes after injection both chelates mainly localize at the kidneys and the liver which 
correlates with a rapid body excretion. Nevertheless we have to consider that, in both 
cases, the somewhat high activity in the blood at this time results in a lack of 
biospecificity as every organ with good blood irrigation has an increased chelate 
concentration. However, there are some differences in the way the two chelates are 
excreted. It can be seen that [67Ga](DOTAC16)- is much more hepatospecific 
(approximately 1.7% of the activity is present in hepatobiliary transit at 30 min) than 
[67Ga](DOTAC10)- (just approximately 0.4% of the activity is present in hepatobiliary 
transit at the same time). These effects can be explained considering the higher 
lipophilicity of [67Ga](DOTAC16)- (logP = 0.27) in comparison to [67Ga](DOTAC10)- 
(logP = -1.50), which results in a higher kidney uptake (0.9% of the activity) for the  
last chelate. It would be expected that the lung uptake of  [67Ga](DOTAC16)- would be 
much higher than that observed, due to the formation of pre-micellar aggregates, which 
could be trapped in lung capillaries, as it has been observed for the long chain tracer 
[153Sm](EPTPAC16)]2- [25]. From the biodistribution data it is noticeable that most of 
the radioactivity was cleared off from the tissues and organs within 24 h with virtually 
no deposition in the bones which is a clear indication of the high chelates stability. 
 According to the specifications of the [67Ga](citrate) supplier, less than 4.5 ng of 
Ga(III) (1 mCi) should be present in the final solution of [67Ga](DOTAC10)- or 
[67Ga](DOTAC16)-. Thus, in both cases, the concentrations were well below the cmc 
determined for the complexes, and no micelles were supposed to be present in solution. 
 
4. Conclusions 
We have developed an easy and efficient synthetic route that leads to DOTA-
based amphiphilic chelators, suitable for gallium(III) complexation. This synthetic 
approach makes use of an orthogonal protection strategy that is well-suited for the 
conjugation to biomolecules bearing a free amine function. 
The in vitro evaluation of [67Ga](DOTAC10)- in serum demonstrated its high 
stability toward transchelation. The biodistribution studies in Wistar rats with the 67Ga-
labeled chelates showed that their uptake occurs mainly in the liver and, as expected, is 
proportional to the length of the pendant α–alkyl chain and consequently to the 
lipophilicity. Their clearance from the body after 24 hours is also noticeable indicating 
that the chelates are very stable and no toxicity effects are foreseen.  
As previously found by us for the analogous NOTA-based Ga(III) chelates [13], 
the injection of the radiochelates at concentrations below the determined cmc precluded 
the formation of micelles in vivo, with lower hepatic uptake than expected. Despite the 
similar in vivo results obtained for the triaza- and tetraaza-based complexes, the tetraaza 
chelators, besides being somewhat more hydrophilic, offer the possibility of covalent 
coupling to biomolecules via a non-coordinating carboxylic moiety, without 
compromising the chelate stability. Preliminary work of conjugation of these 
amphiphilic chelators to model linear RDG peptides stresses the utility of this family of 
Ga(III) chelators, whose lipophilicity can be tuned in accordance to the pendant alkyl 
chain length used. 
 
5. Abbreviations 
%ID/g = percentage of injected dose per gram of tissue 
ANS = 8-anilino-1-naphtalene sulfonic acid 
cmc = critical micellar concentration 
DDM = diphenyldiazomethane 
DLS = dynamic light scattering 
EPTPAC16 = ethylenepropylenetriaminepentaacetic acid 
HEPES = N-(2-Hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) 
ITLC (instant thin layer chromatograpy) 
L = ligand 
MRI = magnetic resonance imaging 
PET = positron emission tomography  
RGD = Arginine-Glycine-Aspartic Acid 
TFA = trifluoracetic acid 
TLC = thin layer chromatography 
TMS = tetramethylsilane 
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 Scheme 1 – Schematic synthesis of DOTAC8, DOTAC10 and DOTAC16. 
 
 Figure 1 – Fluorescence intensity at 480 nm versus: A – [Ga(DOTAC8)-] concentration; B – 
[Ga(DOTAC10)-] concentration; C – [Ga(DOTAC16)-]. 
 
 Figure 2 – Biodistribution profile for Wistar rats (percentage of the injected dose/g of organ) of 
[67Ga](DOTAC10)- (grey bars) and [67Ga](DOTAC16)- (white bars) at 30 min (A) and 24 h (B) after 
injection. 
 
 
 
